AXDX Accelerate Diagnostics Inc

Price (delayed)

$1.27

Market cap

$28M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.46

Enterprise value

$53.81M

Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. The Accelerate Pheno® system and Accelerate PhenoTest® BC ...

Highlights
Accelerate Diagnostics's EPS has increased by 39% YoY and by 10% from the previous quarter
The company's net income rose by 10% YoY and by 4.2% QoQ
The quick ratio has soared by 122% YoY but it fell by 16% QoQ
AXDX's debt is down by 48% YoY but it is up by 3% QoQ
The gross profit has decreased by 36% YoY and by 11% QoQ
The gross margin fell by 33% YoY and by 12% QoQ

Key stats

What are the main financial stats of AXDX
Market
Shares outstanding
22.05M
Market cap
$28M
Enterprise value
$53.81M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
2.01
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.42
Earnings
Revenue
$12.17M
EBIT
-$49.44M
EBITDA
-$46.13M
Free cash flow
-$36.82M
Per share
EPS
-$4.46
Free cash flow per share
-$1.92
Book value per share
-$1.19
Revenue per share
$0.63
TBVPS
$1.6
Balance sheet
Total assets
$30.72M
Total liabilities
$56.5M
Debt
$40.42M
Equity
-$25.78M
Working capital
$8M
Liquidity
Debt to equity
-1.57
Current ratio
1.5
Quick ratio
1.11
Net debt/EBITDA
-0.56
Margins
EBITDA margin
-379.1%
Gross margin
18.6%
Net margin
-485.3%
Operating margin
-395.5%
Efficiency
Return on assets
-156.1%
Return on equity
N/A
Return on invested capital
-182.8%
Return on capital employed
-338.8%
Return on sales
-406.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AXDX stock price

How has the Accelerate Diagnostics stock price performed over time
Intraday
1.6%
1 week
12.39%
1 month
8.55%
1 year
-80.37%
YTD
-67.6%
QTD
8.55%

Financial performance

How have Accelerate Diagnostics's revenue and profit performed over time
Revenue
$12.17M
Gross profit
$2.26M
Operating income
-$48.12M
Net income
-$59.05M
Gross margin
18.6%
Net margin
-485.3%
The gross profit has decreased by 36% YoY and by 11% QoQ
The gross margin fell by 33% YoY and by 12% QoQ
The operating income has increased by 24% year-on-year and by 11% since the previous quarter
Accelerate Diagnostics's operating margin has increased by 21% YoY and by 12% from the previous quarter

Growth

What is Accelerate Diagnostics's growth rate over time

Valuation

What is Accelerate Diagnostics stock price valuation
P/E
N/A
P/B
N/A
P/S
2.01
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.42
Accelerate Diagnostics's EPS has increased by 39% YoY and by 10% from the previous quarter
AXDX's equity is up by 33% YoY but it is down by 30% QoQ
AXDX's price to sales (P/S) is 94% less than its 5-year quarterly average of 34.0 and 59% less than its last 4 quarters average of 5.0
The revenue has declined by 3.5% year-on-year

Efficiency

How efficient is Accelerate Diagnostics business performance
Accelerate Diagnostics's return on invested capital has shrunk by 62% YoY but it has increased by 14% QoQ
Accelerate Diagnostics's ROA has decreased by 49% YoY and by 9% from the previous quarter
Accelerate Diagnostics's ROS has increased by 17% YoY and by 8% from the previous quarter

Dividends

What is AXDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AXDX.

Financial health

How did Accelerate Diagnostics financials performed over time
The company's total assets is 46% lower than its total liabilities
The company's current ratio has surged by 138% YoY but it fell by 26% QoQ
The quick ratio has soared by 122% YoY but it fell by 16% QoQ
AXDX's debt is down by 48% YoY but it is up by 3% QoQ
AXDX's equity is up by 33% YoY but it is down by 30% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.